Compare ANTX & RMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANTX | RMAX |
|---|---|---|
| Founded | 2017 | 1973 |
| Country | United States | United States |
| Employees | N/A | 519 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.6M | 193.2M |
| IPO Year | 2022 | 2013 |
| Metric | ANTX | RMAX |
|---|---|---|
| Price | $4.60 | $9.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.00 | ★ $11.40 |
| AVG Volume (30 Days) | 214.1K | ★ 1.3M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.56 | N/A |
| EPS | N/A | ★ 0.60 |
| Revenue | N/A | ★ $195,929,000.00 |
| Revenue This Year | N/A | $2.62 |
| Revenue Next Year | N/A | $1.24 |
| P/E Ratio | ★ N/A | $15.82 |
| Revenue Growth | N/A | ★ 11.13 |
| 52 Week Low | $1.00 | $5.46 |
| 52 Week High | $6.91 | $11.62 |
| Indicator | ANTX | RMAX |
|---|---|---|
| Relative Strength Index (RSI) | 57.17 | 57.22 |
| Support Level | $1.06 | $8.10 |
| Resistance Level | $5.14 | $9.65 |
| Average True Range (ATR) | 0.42 | 0.51 |
| MACD | -0.05 | -0.25 |
| Stochastic Oscillator | 54.07 | 26.25 |
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.